

**Supplementary Table 1.** Annual percentage change in incidence by age groups and ICC3 site-groups (malignant only), Estonia 1970–2016

	0–4 years		5–9 years		10–14 years	
	APC (%)	95% CI	APC (%)	95% CI	APC (%)	95% CI
<b>All sites</b>	0.7	-0.2–1.5	0.1	-0.5–0.7	<b>0.6</b>	<b>0.1–1.2</b>
<b>I Leukemias, myeloproliferative diseases, and myelodysplastic diseases</b>	0.0	-0.9–1.0	0.4	-0.5–1.2	0.6	-1.2–2.5
<b>II. Lymphomas and reticuloendothelial neoplasms</b>	1.0	-0.7–2.7	-1.6	-3.5–0.3	0.7	-0.9–2.3
<b>III. CNS and miscellaneous intracranial and intraspinal neoplasms (malignant only)</b>	1.5	-0.6–3.6	7.6 <sup>a</sup>	-2.3–18.6	0.2	-1.6–2.0
<b>IV. Neuroblastoma and other peripheral nervous cell tumors</b>	<b>3.1</b>	<b>1.3–5.0</b>	-1.6	-4.4–1.2	-0.8	-11.7–11.5
<b>V. Retinoblastoma</b>	0.9	-2.6–4.5	NC		NC	
<b>VI. Renal tumors</b>	-1.1	-3.3–1.2	0.8	-4.4–6.2	NC	
<b>VII. Hepatic tumors</b>	2.4	-1.3–6.2	NC		NC	
<b>VIII. Malignant bone tumors</b>	NC		1.7	-4.2–8.0	-1.3	-4.1–1.6
<b>IX. Soft tissue and other extraosseous sarcomas</b>	1.6	-0.5–3.7	1.2	-3.5–6.1	1.0	-2.8–5.0
<b>X. Germ cell tumors, trophoblastic tumors, and neoplasms of gonads</b>	<b>2.7</b>	<b>0.4–5.1</b>	NC		1.2	-2.4–5.0
<b>XI. Other malignant epithelial neoplasms and malignant melanomas</b>	NC		NC		2.0	-0.4–4.4
<b>XII. Other and unspecified malignant neoplasms</b>	<b>-3.4</b>	<b>-5.9;0.8</b>	NC		NC	

<sup>a</sup>joinpoint in 1985

NC not calculated, for sites with less than 10 cases over the study period

Statistically significant findings marked in bold